Ken Griffin Clovis Oncology, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.85 $305,595 - $829,472	-291,043 Reduced 69.13%	129,979 $155,000
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $75,909 - $356,656	-120,492 Reduced 22.25%	421,022 $758,000
Q1 2022 May 16, 2022	BUY	$1.43 - $3.14 $607,565 - $1.33 Million	424,871 Added 364.25%	541,514 $1.09 Million
Q4 2021 Feb 14, 2022	SELL	$2.7 - $4.76 $70,902 - $124,997	-26,260 Reduced 18.38%	116,643 $316,000
Q3 2021 Nov 15, 2021	BUY	$4.06 - $5.8 $67,286 - $96,123	16,573 Added 13.12%	142,903 $637,000
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $102,141 - $143,446	20,347 Added 19.2%	126,330 $732,000
Q1 2021 May 17, 2021	SELL	$4.81 - $10.34 $8.43 Million - $18.1 Million	-1,751,752 Reduced 94.3%	105,983 $744,000
Q4 2020 Feb 16, 2021	BUY	$4.13 - $6.41 $1.38 Million - $2.14 Million	333,219 Added 21.86%	1,857,735 $8.92 Million
Q3 2020 Nov 16, 2020	SELL	$4.82 - $7.72 $326,810 - $523,439	-67,803 Reduced 4.26%	1,524,516 $8.89 Million
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $7.96 Million - $13.6 Million	1,399,165 Added 724.38%	1,592,319 $10.7 Million
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $2.61 Million - $14.3 Million	-868,712 Reduced 81.81%	193,154 $2.01 Million
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $1.08 Million - $4.23 Million	-275,294 Reduced 20.59%	1,061,866 $4.17 Million
Q2 2019 Aug 14, 2019	BUY	$12.81 - $25.67 $8.48 Million - $17 Million	662,090 Added 98.08%	1,337,160 $19.9 Million
Q1 2019 May 15, 2019	BUY	$17.66 - $30.28 $1.12 Million - $1.91 Million	63,138 Added 10.32%	675,070 $0
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $9.48 Million - $26.6 Million	-814,946 Reduced 57.11%	611,932 $11 Million
Q3 2018 Nov 13, 2018	BUY	$29.37 - $49.48 $14.4 Million - $24.3 Million	491,149 Added 52.49%	1,426,878 $0
Q2 2018 Aug 10, 2018	SELL	$42.06 - $62.4 $6.59 Million - $9.78 Million	-156,680 Reduced 14.34%	935,729 $0
Q1 2018 May 11, 2018	BUY	$50.12 - $67.72 $48.4 Million - $65.4 Million	965,606 Added 761.5%	1,092,409 $57.7 Million
Q4 2017 Feb 09, 2018	SELL	$57.69 - $84.58 $70.8 Million - $104 Million	-1,228,025 Reduced 90.64%	126,803 $8.62 Million
Q3 2017 Nov 09, 2017	BUY	$67.17 - $84.81 $91 Million - $115 Million	1,354,828	1,354,828 $112 Million

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account